US pharma giant Pfizer (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Dr Chris Boshoff, as chief scientific officer and ...

Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend ...

Shanghai-based Zai Lab (HKEX: 9688) and New York-based Pfizer (NYSE: PFE) are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. The agreement grants Pfizer’s ...

NEW YORK (Reuters) - Pfizer (PFE) is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant. With business and stock excess seemingly totally wrung out, and with ...

After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to slim down by divesting its hospital drugs unit, Reuters reports ...

Get detailed information on Clobetasol Propinate, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...

Eyenovia, Inc. EYEN announced the decision to terminate a phase III study evaluating its investigational drug-device product, ...

The unit was established following Pfizer’s acquisition of Hospira in 2015. Credit: Pfizer. Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly ...

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...